Gender, n (%) |
|
Male |
33 (60) |
Female |
22 (40) |
Solid organ, n (%) |
|
Heart |
28 (51) |
Kidney |
9 (16) |
Multivisceral |
7 (13) |
Liver |
6 (11) |
Lung |
5 (9) |
Immunosuppression, n (%)
≥ 2 agents including tacrolimus
≥ 2 agents no tacrolimus
Tacrolimus only
Cyclosporine only
Disease Characteristics, n=55
Sub-type, n (%)
DLBCL
Burkitt lymphoma
NK/T cell lymphoma
Other
Stage, n (%)
|
31 (56)
1 (2)
21 (38)
2 (4)
23 (42)
25 (45)
5 (9)
2 (4)
|
I
II
III
IV
Unknown/incomplete staging
EBER positive, n (%)
|
4 (7)
8 (15)
31 (56)
10 (18)
2 (4)
|
Yes
No
|
35 (64)
17 (31)
|
Unknown
First line treatment, n (%)
RIS
Rituximab with chemotherapy
Ritiximab without chemotherapy
Chemotherapy
LMB-96
Cyclophosphamide & prednisone
Other
|
3 (5)
49 (89)
40 (73)
4 (7)
46 (84)
22 (40)
14 (26)
10 (18)
|